Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue: +21.8%
EPS: −80.6%
Free cash flow: +6.78%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

44.61 1.28 −2.79%

Follow ALKS

Alert me

Market cap: $7.5B
P/E: 0.0×
Fwd P/E: −85.9×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alkermes plc (ALKS) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Alkermes plc (ALKS) trades at a price to free cash flow of 32.8×. Over the past ten years it has ranged from 0.0× (June 2023) to 1,150× (October 2018); the current reading is higher than 69% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ALKS/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Alkermes plc price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ALKS/metrics/price-to-free-cash-flow">Alkermes plc (ALKS) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	9.6×	(18.27%)
FY2024	11.7×	(12.93%)
FY2023	13.5×	—
FY2022	0.0×	—
FY2021	47.1×	(34.09%)
FY2020	71.5×	—
FY2019	0.0×	—
FY2018	140×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	29.8×	(24.23%)
Jun 2026	39.3×	47.91%
Mar 2026	26.6×	177.56%
Dec 2025	9.6×	(5.12%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 1,150×

Ten-year median 11.4×

Current reading's percentile 69

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
LNTH Lantheus Holdings, Inc. compare	16.9×
LQDA Liquidia Corporation compare	26.4×
ALKS Alkermes plc	32.8×
ELAN Elanco Animal Health Incorporated compare	33.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
SUPN Indivior Pharmaceuticals Inc. compare	115×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Alkermes plc (ALKS) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ALKS

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ALKS

Stockrow Weekly